推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733,021-34243363

chinasupport@letpub.com

登录 注册 新注册优惠

Targeted Oncology

2024年6月最新影响因子数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎点击此处反馈给我们。

按期刊名首写字母查看 TARGET ONCOL最新评论:肿瘤的文章很容易啊,一下就录用 (2023-07-18)


期刊名:   ISSN:   研究方向:   影响因子: -   SCI收录:
大类学科:   小类学科:   中国科学院分区:   是否OA期刊:   结果排序:

同行评审状态查询 Manuscript Number * Last Name * First Name * 出版社 * 查 询 重 置

按研究方向查看:


Targeted Oncology期刊基本信息Hello,您是该期刊的第37045位访客


基本信息 登录收藏
期刊名字Targeted OncologyTargeted Oncology

TARGET ONCOL
(此期刊被最新的JCR期刊SCIE收录)

LetPub评分
7.3
50人评分
我要评分

声誉
8.8

影响力
6.1

速度
7.0

期刊ISSN1776-2596
微信扫码收藏此期刊
E-ISSN1776-260X
2023-2024最新影响因子
(数据来源于搜索引擎)
4.4 点击查看影响因子趋势图
实时影响因子 截止2024年10月29日:2.877
2023-2024自引率2.30%点击查看自引率趋势图
五年影响因子3.9
JCI期刊引文指标 0.85
h-index 35
CiteScore
2024年最新版
CiteScoreSJRSNIPCiteScore排名
8.401.4210.949
学科分区排名百分位
大类:Medicine
小类:Pharmacology (medical)
Q132 / 272
大类:Medicine
小类:Oncology
Q176 / 404
大类:Medicine
小类:Cancer Research
Q269 / 230

期刊简介
Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology. The journal includes:

Original Research Articles on all aspects of molecularly targeted agents for the treatment of cancer, including immune checkpoint inhibitors and related approaches.
Comprehensive narrative Review Articles and shorter Leading Articles discussing relevant clinically established as well as emerging agents and pathways.
Current Opinion articles that place interesting areas in perspective.
Therapy in Practice articles that provide a guide to the optimum management of a condition and highlight practical, clinically relevant considerations and recommendations.
Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement.
Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.
期刊官方网站https://www.springer.com/11523
期刊投稿网址https://www.editorialmanager.com/targ
作者指南网址https://www.springer.com/11523/submission-guidelines
期刊语言要求Language
Presenting your work in a well-structured manuscript and in well-written English gives it its best chance for editors and reviewers to understand it and evaluate it fairly. Many researchers find that getting some independent support helps them present their results in the best possible light.

经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足Targeted Oncology的语言要求,还能让Targeted Oncology编辑和审稿人得到更好的审稿体验,让稿件最大限度地被Targeted Oncology编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢
提交文稿
是否OA开放访问No
通讯方式SPRINGER, VAN GODEWIJCKSTRAAT 30, DORDRECHT, NETHERLANDS, 3311 GZ
出版商Springer International Publishing
涉及的研究方向医学-肿瘤学
出版国家或地区FRANCE
出版语言English
出版周期Quarterly
出版年份2006
年文章数 70点击查看年文章数趋势图
Gold OA文章占比51.26%
研究类文章占比:
文章 ÷(文章 + 综述)
75.71%
WOS期刊SCI分区
2023-2024年最新版
WOS分区等级:2区

按JIF指标学科分区收录子集JIF分区JIF排名JIF百分位
学科:ONCOLOGYSCIEQ286/322
按JCI指标学科分区收录子集JCI分区JCI排名JCI百分位
学科:ONCOLOGYSCIEQ2100/322
中国科学院《国际期刊预警
名单(试行)》名单
2024年02月发布的2024版:不在预警名单中

2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:不在预警名单中

2020年12月发布的2020版:不在预警名单中
中国科学院SCI期刊分区
2023年12月最新升级版
点击查看中国科学院SCI期刊分区趋势图
大类学科小类学科Top期刊综述期刊
医学 1区3区4区
ONCOLOGY
肿瘤学
1区1区3区
中国科学院SCI期刊分区
2022年12月升级版
大类学科小类学科Top期刊综述期刊
医学 1区3区3区
ONCOLOGY
肿瘤学
4区1区4区
中国科学院SCI期刊分区
2021年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学 1区3区4区
ONCOLOGY
肿瘤学
3区1区4区
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)
Scopus (CiteScore)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1776-2596%5BISSN%5D
平均审稿速度网友分享经验:
>12周,或约稿
平均录用比例网友分享经验:
较易
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)后论文在Targeted Oncology顺利发表。
快看看作者怎么说吧:服务好评 论文致谢
期刊常用信息链接
同领域相关期刊 Targeted Oncology期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 Targeted Oncology中国科学院SCI期刊分区趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
Targeted Oncology上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 中国科学院分区趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发文
  • 中国科学院分区相关期刊
  • 同类著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144873.20
    Nature Reviews Clinical Oncology12799.40
    NATURE REVIEWS CANCER396111.90
    ANNALS OF ONCOLOGY21063.90
    CANCER CELL29555.20
    JOURNAL OF CLINICAL ONCOLOGY49441.20
    LANCET ONCOLOGY27462.10
    CANCER RESEARCH41116.10
    SEMINARS IN CANCER BIOLOGY13426.80
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH6718.20
    中国科学院SCI期刊分区同大类学科的热搜期刊 浏览次数
    MEDICINE671819
    BIOMATERIALS563289
    BIOMEDICINE & PHARMACOTHERAPY547076
    Frontiers in Pharmacology511013
    Journal of Materials Chemistry B500004
    Frontiers in Immunology487324
    COMPUTERS IN BIOLOGY AND MEDICINE467694
    JOURNAL OF ETHNOPHARMACOLOGY461823
    COLLOIDS AND SURFACES B-BIOINTERFACES436249
    Frontiers in Oncology432694
  •  

    Targeted Oncology Targeted Oncology
    我来预测明年:
    稳步上升 表现平稳 逐渐下降  刷新
  •  

     
  •  

     
  •  

     
  • 中国学者近期发表的论文
    1.Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies

    Author: Popat, Sanjay; Ahn, Myung-Ju; Ekman, Simon; Leighl, Natasha B.; Ramalingam, Suresh S.; Reungwetwattana, Thanyanan; Siva, Shankar; Tsuboi, Masahiro; Wu, Yi-Long; Yang, James Chih-Hsin
    Journal: TARGETED ONCOLOGY. 2023; Vol. 18, Issue 1, pp. 9-24. DOI: 10.1007/s11523-022-00941-7
        PubMed      DOI
    2.Distribution of <Emphasis Type="Italic">ALK</Emphasis> Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib

    Author: Yudong Su, Xiang Long, Yang Song, Peng Chen, Shanqing Li, Huaxia Yang, Pancheng Wu, Yanyu Wang, Zhongxing Bing, Zhili Cao, Lei Cao, Yijun Wu, Zhe Zhang, Jing Liu, Bing Li, Jianxing Xiang, Ke Ma, Tengfei Zhang, Lu Zhang, Xinru Mao, Hao Liu, Puyuan Xing, Naixin Liang
    Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-019-00631-x
        DOI
    3.Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study

    Author: Xiaonan Hong, Yuqin Song, Huiqiang Huang, Bing Bai, Huilai Zhang, Xiaoyan Ke, Yuankai Shi, Jun Zhu, Guodong Lu, Stefan Liebscher, Chunxiao Cai
    Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-019-00630-y
        DOI
    4.Clinical Management of Non-Small Cell Lung Cancer with Concomitant <Emphasis Type="Italic">EGFR</Emphasis> Mutations and <Emphasis Type="Italic">ALK</Emphasis> Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib

    Author: Yiming Zhao, Shuyuan Wang, Bo Zhang, Rong Qiao, Jianlin Xu, Lele Zhang, Yanwei Zhang, Baohui Han
    Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-019-00628-6
        DOI
    5.Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors

    Author: Xiang Chen, JiaXi Yao, Li Liu, WenZhong Zheng, XiaoYi Hu, YanJun Zhu, Hang Wang, JianMing Guo
    Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-019-00625-9
        DOI
    6.Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy

    Author: Zhuanglin Li, Mingxue Wang, Xuejing Yao, Wenting Luo, Yaocheng Qu, Deling Yu, Xue Li, Jianmin Fang, Changjiang Huang
    Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-018-0616-8
        DOI
    7.Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy

    Author: Xia Yang, Jia Rao, Wentao Yang, Ruohong Shui
    Journal: Targeted Oncology, 2018, Vol.13, 757-767, DOI:10.1007/s11523-018-0602-1
        DOI
    8.Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis

    Author: Gaofeng Pan, Shaobo Ke, Jinping Zhao
    Journal: Targeted Oncology, 2013, Vol.8, 107-116, DOI:10.1007/s11523-013-0272-y
        DOI
    9.Hyperbaric oxygen and cancer: more complex than we expected

    Author: Liu Wenwu, Sun Xuejun, Tao Hengyi, Liu Kan
    Journal: Targeted Oncology, 2013, Vol.8, 79-81, DOI:10.1007/s11523-013-0259-8
        DOI
    10.Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis

    Author: Xue Li, Minghuan Li, Zhen Lian, Hui Zhu, Li Kong, Ping Wang, Jinming Yu
    Journal: Targeted Oncology, 2016, Vol.11, 753-761, DOI:10.1007/s11523-016-0451-8
        DOI
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144873.20
    NATURE REVIEWS DRUG DISCOVERY289137.40
    LANCET700148.10
    NEW ENGLAND JOURNAL OF MEDICINE933145.40
    BMJ-British Medical Journal019.90
    BMJ-British Medical Journal019.90
    Nature Reviews Clinical Oncology12799.40
    Nature Reviews Disease Primers4876.70
    NATURE REVIEWS CANCER396111.90
    NATURE REVIEWS IMMUNOLOGY35193.40
    同分区等级的其他期刊名称 h-index CiteScore
    Computational Visual Media016.90
    Industrial and Organizational Psychology-Perspectives on Science and Practice07.70
    COMMUNICATIONS OF THE ACM18916.10
    MedComm06.70
    Journal of Econometrics1358.60
    CLINICAL NUCLEAR MEDICINE532.90
    Journal of International Financial Management & Accounting09.10
    BMJ Evidence-Based Medicine08.90
    ARCHIVOS DE BRONCONEUMOLOGIA413.50
    ARCHIVOS DE BRONCONEUMOLOGIA463.50
以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分:

同领域作者分享投稿经验:共31


    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2024 中国: LetPub上海    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)

    增值电信业务经营许可证:沪B2-20211595    网络文化经营许可证:沪网文[2023]2004-152号

    礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室